In addition, FTO is overexpressed in AML patients carrying t(11q23)/MLL rearrangements, t(15; 17)/PML-RARA fusion, FLT3-ITD and/or NPM1 mutations. This evidence concerns the gene FTO and acute myeloid leukemia.